Effects of the enternal administration of Bifidobacterium breve (BBG-01, Yakult) for dysbiosis of infants born by C-section on of their growth and development

Effects of the enternal administration of Bifidobacterium breve (BBG-01, Yakult) for dysbiosis of infants born by C-section on of their growth and development - Probiotics for C-section born infants

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036526

Enrollment

Registered

2019-04-16

Start date

2019-05-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infants born by C-section

Interventions

Daily supplement of bifidobacterial from the 1st day of life for one month Daily supplement of placebo from the 1st day of life for one month

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Apparently healthy newborns by C-section

Exclusion criteria

Exclusion criteria: Newborn those who are judged in appropriate for the enrollment for the study by one of doctors who performed C-section, charged for the study or the final responsibility

Design outcomes

Primary

Measure	Time frame
Improvement of dysbiosis, including early colonization and its persistence of bifidobacteria	—

Secondary

Measure	Time frame
1. Infant growth and development, 2. Intestinal microbiota, 3. Intestinal environment	—

Countries

Japan

Contacts

Public ContactYuichiro Yamashiro

Juntendo University Graduate School of Medicine Probiotics Research Laboratory

yamasiro@juntendo.ac.jp03-5689-0082

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026